VANCOUVER, British Columbia, May 9, 2005 (PRIMEZONE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, today announced that the company's CEO, Dr. Janet Greeson, was interviewed on Schaffers Research by Bram Solloway on Streetcast.tv.
The interview highlighted the progress the organization has been making over the past few years. Greeson also offers further insights into her confidence in the future of the company and of the biopharmaceuticals industry.
To watch the entire interview, visit www.streetcast.tv or tune into the America One Cable TV News Network. The interview can be accessed on the site by clicking on the Schaffers Research Billboard which is left of the tv player broadcast box.
About Samaritan Pharmaceuticals
"A Cure Is Closer Than You Think"
Samaritan, a small biopharmaceutical company, is committed to winning the race to approval for its life-saving affordable drugs. Samaritan, in collaboration with Georgetown University, is advancing its proprietary compounds for AIDS, Alzheimer's, cancer and cardiovascular disease.
For more information visit www.samaritanpharma.com.
About Streetcast.tv
Streetcast.tv is an Internet Television Broadcaster providing current financial news and content on the Equities Markets. The broadcast is seen on the America One Cable Television Network. America One Television is a 24-hour broadcast network that provides programming to over 30 million households via 127 broadcast affiliate stations located in 40 states.
Safe Harbor Statement
Disclaimer: The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.